190 related articles for article (PubMed ID: 36769210)
1. Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology.
Pereira M; Vale N
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769210
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey.
Sayan M; Sultanoglu N; Sanlidag T
AIDS Res Hum Retroviruses; 2023 Feb; 39(2):84-90. PubMed ID: 36301912
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine.
Sariyer IK; Gordon J; Burdo TH; Wollebo HS; Gianti E; Donadoni M; Bellizzi A; Cicalese S; Loomis R; Robinson JA; Carnevale V; Steiner J; Ozdener MH; Miller AD; Amini S; Klein ML; Khalili K
Mol Ther; 2019 Dec; 27(12):2067-2079. PubMed ID: 31653397
[TBL] [Abstract][Full Text] [Related]
4. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
[TBL] [Abstract][Full Text] [Related]
5. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
6. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
[TBL] [Abstract][Full Text] [Related]
7. Formulation and pharmacology of long-acting rilpivirine.
Williams PE; Crauwels HM; Basstanie ED
Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
[TBL] [Abstract][Full Text] [Related]
8. Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
Penrose KJ; Brumme CJ; Scoulos-Hanson M; Hamanishi K; Gordon K; Viana RV; Wallis CL; Harrigan PR; Mellors JW; Parikh UM
Antivir Chem Chemother; 2018; 26():2040206618762985. PubMed ID: 29566538
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
Vannappagari V; Ragone L; Henegar C; van Wyk J; Brown D; Demarest J; Quercia R; St Clair M; Underwood M; Gatell JM; de Ruiter A; Aboud M
Antivir Ther; 2019; 24(6):393-404. PubMed ID: 31503008
[TBL] [Abstract][Full Text] [Related]
10. An unusual case of underlying rilpivirine resistance in an antiretroviral-naïve man with AIDS.
Skalweit MJ
Int J STD AIDS; 2016 Dec; 27(14):1346-1349. PubMed ID: 27074792
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
Qazzaz H; Parganas C; Cory TJ
Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
[TBL] [Abstract][Full Text] [Related]
12. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.
Hayashida T; Hachiya A; Ode H; Nishijima T; Tsuchiya K; Sugiura W; Takiguchi M; Oka S; Gatanaga H
J Antimicrob Chemother; 2016 Oct; 71(10):2760-6. PubMed ID: 27330069
[TBL] [Abstract][Full Text] [Related]
13.
Giacobbi NS; Sluis-Cremer N
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507107
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
[TBL] [Abstract][Full Text] [Related]
15. Rilpivirine resistance associated mutations in HIV-1 infected pregnant women.
Cecchini DM; Zapiola I; Rodriguez CG; Bouzas MB
Enferm Infecc Microbiol Clin; 2015; 33(7):498-9. PubMed ID: 25639908
[No Abstract] [Full Text] [Related]
16. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
James C; Preininger L; Sweet M
Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
[TBL] [Abstract][Full Text] [Related]
17. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
18. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Schafer JJ; Short WR
Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
[TBL] [Abstract][Full Text] [Related]
19. Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.
Calvez V; Marcelin AG; Vingerhoets J; Hill A; Hadacek B; Moecklinghoff C
Antivir Ther; 2016; 21(5):405-12. PubMed ID: 26761642
[TBL] [Abstract][Full Text] [Related]
20. Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.
Saravanan S; Kausalya B; Gomathi S; Sivamalar S; Pachamuthu B; Selvamuthu P; Pradeep A; Sunil S; Mothi SN; Smith DM; Kantor R
AIDS Res Hum Retroviruses; 2017 Jun; 33(6):567-574. PubMed ID: 27869478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
